Precio de cierre
Otros sitios de cotización
|
||
- USD | - |
|
10/07 | Jazz Pharmaceuticals plc asciende a Samantha Pearce a Directora Comercial | CI |
20/06 | JAZZ PHARMACEUTICALS PLC : Needham & Co. mantiene su recomendación de compra | ZM |
Ventas 2024 * | 4051,99 M 3716,98 M | Ventas 2025 * | 4361,43 M 4000,83 M | Capitalización | 6690,29 M 6137,15 M |
---|---|---|---|---|---|
Resultado Neto 2024 * | 425 M 390 M | Resultado Neto 2025 * | 593 M 544 M | VE / Ventas 2024 * | 2,44 x |
Deuda neta 2024 * | 3180,65 M 2917,68 M | Deuda neta 2025 * | 1842,2 M 1689,89 M | VE / Ventas 2025 * | 1,96 x |
P/E ratio 2024 * |
18
x | P/E ratio 2025 * |
12,4
x | Empleados | - |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 97,22 % |
Último transcript sobre Jazz Pharmaceuticals, Inc.
Directores | Puesto | Edad | Desde |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 01/03/03 |
Renée Galá
PSD | President | 52 | 16/03/20 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 29/05/19 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 01/03/03 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13/05/13 |
Patrick Enright
BRD | Director/Board Member | 62 | 01/01/09 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+61,53 % | 856 mil M | |
+38,95 % | 631 mil M | |
-3,66 % | 359 mil M | |
+15,06 % | 325 mil M | |
+9,18 % | 297 mil M | |
+5,89 % | 234 mil M | |
+16,53 % | 226 mil M | |
+15,67 % | 177 mil M | |
+2,47 % | 165 mil M |